Literature DB >> 34396392

RE: Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.

Natalie Klar1, Sylvia Adams1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34396392      PMCID： PMC8755500          DOI： 10.1093/jnci/djab152

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   11.816


× No keyword cloud information.
  2 in total

1.  Selection of Adjuvant Endocrine Therapy for Women With Breast Cancer in Menopausal Transition: Is It Simpler Than We Thought?

Authors:  Shaveta Vinayak; Nancy E Davidson
Journal:  J Natl Cancer Inst       Date:  2021-11-02       Impact factor: 11.816

2.  Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.

Authors:  Gwen M H E Dackus; Katarzyna Jóźwiak; Gabe S Sonke; Elsken van der Wall; Paul J van Diest; Sabine Siesling; Michael Hauptmann; Sabine C Linn
Journal:  J Natl Cancer Inst       Date:  2021-11-02       Impact factor: 13.506
  2 in total
  1 in total

1.  Response to Klar and Adams.

Authors:  Gwen M H E Dackus; Katarzyna Jóźwiak; Michael Hauptmann; Sabine C Linn
Journal:  J Natl Cancer Inst       Date:  2022-01-11       Impact factor: 11.816
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.